{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01222039",
      "OrgStudyIdInfo": {
        "OrgStudyId": "EudraCT: 2008-004014-27"
      },
      "Organization": {
        "OrgFullName": "Andalusian Network for Design and Translation of Advanced Therapies",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Multicenter Clinical Trial for the Evaluation of Mesenchymal Stem Cells From Adipose Tissue in Patients With Chronic Graft Versus Host Disease.",
      "OfficialTitle": "Multicenter Clinical Trial Phase I/II Randomized, Controlled, for the Evaluation of Safety and Feasibility of Therapy With Two Different Doses of Allogenic Mesenchymal Stem Cells From Adipose Tissue in Patients With Chronic Graft Versus Host Disease.",
      "Acronym": "CMM/EICH/2008"
    },
    "StatusModule": {
      "StatusVerifiedDate": "November 2016",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "June 2010"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "June 2014",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "June 2014",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "October 14, 2010",
      "StudyFirstSubmitQCDate": "October 15, 2010",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "October 18, 2010",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "November 17, 2016",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "November 18, 2016",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Iniciativa Andaluza en Terapias Avanzadas",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "The main purpose of this trial is to assess the safety and feasibility of treatment with two-dose infusion of allogeneic mesenchymal stem cells from adipose tissue expanded in vitro in patients undergoing haematopoietic stem cell transplantation (HSCT, who have developed chronic and extensive graft versus host disease (GVHD).\n\nMesenchymal stem cells (MSCs) express low levels of HLA class I molecules, and do not express class II molecules neither CD40, CD80 and CD86, being unable to induce proliferation of allogeneic lymphocytes. In addition, MSCs inhibit lymphocyte proliferation by inhibiting cell division and maintaining these cells in a quiescent state. This supports the hypothesis that MSCs are universal suppressors."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Graft Versus Host Disease",
          "Chronic and Expanded Graft Versus Host Disease",
          "Immune System Diseases"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Graft versus host disease",
          "Mesenchymal stem cell",
          "Allogeneic mesenchymal stem cell",
          "Adipose tissue",
          "Allotransplant",
          "Allogenic",
          "Mesenchymal Stem Cells",
          "Immune System Diseases",
          "Chronic",
          "Expanded"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "19",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Conventional treatment plus high dose: 3x10e6 cells / Kg.",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Other: Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue."
              ]
            }
          },
          {
            "ArmGroupLabel": "Conventional treatment plus low dose: 1x10e6 cells / Kg",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Other: Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue."
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Other",
            "InterventionName": "Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.",
            "InterventionDescription": "Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. Low dose: 1 x10e6 / Kg.\n\nConventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Conventional treatment plus high dose: 3x10e6 cells / Kg.",
                "Conventional treatment plus low dose: 1x10e6 cells / Kg"
              ]
            }
          },
          {
            "InterventionType": "Other",
            "InterventionName": "Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.",
            "InterventionDescription": "Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. High dose: 3 x10e6/Kg.\n\nConventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Conventional treatment plus high dose: 3x10e6 cells / Kg.",
                "Conventional treatment plus low dose: 1x10e6 cells / Kg"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Number of adverse events",
            "PrimaryOutcomeTimeFrame": "24 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Percentage of patients in each group that may potentially reduce corticosteroids at week 7, 20 and 42, started immunosuppressive treatment and percentage of patients at week 56 have been suspended on full immunosuppressive treatment",
            "SecondaryOutcomeTimeFrame": "12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Overall survival and disease-free survival.",
            "SecondaryOutcomeTimeFrame": "12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Changes in lymphocyte subsets and levels of inflammatory and antiinflammatory cytokines in each of the groups.",
            "SecondaryOutcomeTimeFrame": "12 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nPatients who develop chronic extensive GVHD as determined by the National Institute of Health Consensus Development Project on Criteria for Clinical Trials in Chronic GVHD (Biol Blood Marrow Transplant 2005; 11: 945-955), and which meet the following criteria:\n\nThey have never received therapy for chronic GVHD.\nThey have de novo or quiescent chronic extended GVHD.\n\nExclusion Criteria:\n\nConcomitant severe systemic infection.\nOncologic or hematological condition relapse.\nPregnancy.\nEstimated life expectancy less than 1 week.\nPatients who do not give their informed consent.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "65 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Manuel Jurado Chacón, MD",
            "OverallOfficialAffiliation": "Haematology Department, Hospital Universitario Virgen de las Nieves de Granada. Spain.",
            "OverallOfficialRole": "Study Chair"
          },
          {
            "OverallOfficialName": "Ildefonso Espigado, MD",
            "OverallOfficialAffiliation": "Haematology Department, Hospital Universitario Virgen del Rocío de Sevilla, Spain.",
            "OverallOfficialRole": "Principal Investigator"
          },
          {
            "OverallOfficialName": "Carlos Solano Vercet, MD",
            "OverallOfficialAffiliation": "Haematology and Oncology Department. Hospital Clínico Universitario de Valencia, Spain.",
            "OverallOfficialRole": "Principal Investigator"
          },
          {
            "OverallOfficialName": "Sebastián Garzón López., MD",
            "OverallOfficialAffiliation": "Hospital de Jerez de la Frontera, Cádiz. Spain.",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Hospital de Jerez de la Frontera.",
            "LocationCity": "Jerez de la Frontera",
            "LocationState": "Cádiz.",
            "LocationZip": "11407",
            "LocationCountry": "Spain"
          },
          {
            "LocationFacility": "Hospital Universitario Virgen de las Nieves",
            "LocationCity": "Granada.",
            "LocationZip": "18014.",
            "LocationCountry": "Spain"
          },
          {
            "LocationFacility": "Hospital Universitario Virgen del Rocío de Sevilla",
            "LocationCity": "Sevilla",
            "LocationZip": "41013",
            "LocationCountry": "Spain"
          },
          {
            "LocationFacility": "Hospital Clínico de Valencia",
            "LocationCity": "Valencia",
            "LocationZip": "46010",
            "LocationCountry": "Spain"
          }
        ]
      }
    },
    "ReferencesModule": {
      "SeeAlsoLinkList": {
        "SeeAlsoLink": [
          {
            "SeeAlsoLinkLabel": "Andalusian Initiative for Advanced Therapies",
            "SeeAlsoLinkURL": "http://www.juntadeandalucia.es/terapiasavanzadas/"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000006086",
            "ConditionMeshTerm": "Graft vs Host Disease"
          },
          {
            "ConditionMeshId": "D000007154",
            "ConditionMeshTerm": "Immune System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M8341",
            "ConditionBrowseLeafName": "Graft vs Host Disease",
            "ConditionBrowseLeafAsFound": "Graft Versus Host Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafAsFound": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T2832",
            "ConditionBrowseLeafName": "Homologous Wasting Disease",
            "ConditionBrowseLeafAsFound": "Graft Versus Host Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T1303",
            "ConditionBrowseLeafName": "Chronic Graft Versus Host Disease",
            "ConditionBrowseLeafAsFound": "Chronic Graft Versus Host Disease",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M13273",
            "InterventionBrowseLeafName": "Prednisone",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M18113",
            "InterventionBrowseLeafName": "Cyclosporine",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M5882",
            "InterventionBrowseLeafName": "Cyclosporins",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M18102",
            "InterventionBrowseLeafName": "Tacrolimus",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "Infl",
            "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "ANeo",
            "InterventionBrowseBranchName": "Antineoplastic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "Infe",
            "InterventionBrowseBranchName": "Anti-Infective Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "ARhu",
            "InterventionBrowseBranchName": "Antirheumatic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "Derm",
            "InterventionBrowseBranchName": "Dermatologic Agents"
          }
        ]
      }
    }
  }
}